Some predicted that drugmakers might boost launch prices to make up for Medicare drug negotiations shrinking profits. Harvard researchers find no evidence of that happening so far.
News|Videos|January 15, 2026
National health expenditures 2024 recap
Author(s)Logan Lutton
In 2024, U.S. health care spending rose to $5.3 trillion, driven by increased per capita use and demand for medical services as utilization rebounded following the COVID-19 pandemic.
Advertisement
The United States spent $5.3 trillion on health care in 2024, an estimated equivalent of $15,474 per person, according to an analysis
Micah Hartman, statistician in the National Health Services Group at CMS and lead author of the study, and Don Metz, interim editor-in-chief and executive publisher of Health Affairs, co-hosted a press briefing yesterday to share the report highlights.
Advertisement
Related to this article
State PBM reform accelerates through 2026, with Theresa Carnegie of Mintz unpacking new laws, rebate pass-through, spread pricing bans, and compliance risks.
Only 19.1% of commercially insured patients with first-episode psychosis were adherent to antipsychotics in the year after starting treatment.
Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.
Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.
In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Tariffs on patented drugs now apply to all branded drugmakers
2
A head-to-head phase 3b comparison of bimekizumab with risankizumab in active psoriatic arthritis: Written recap
3
Fewer than 1 in 5 young patients with first-episode psychosis adhere to antipsychotics
4
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
5